Mesoblast develops cell therapies for inflammatory diseases, led by Ryoncil, approved in the US for a transplant complication in children. It last closed at $10.89 on Nov 20, down 2.59% on the day. Over the last 12 months MESO insiders bought $37.5M of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is MESO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MESO.
From MESO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Aug 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
StreetAlpha's call on MESOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
MESO · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 23% below its 20 day and 27% below its 50 day average. It is 38% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $10.87, and the nearest resistance the Pivot at $11.07.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 5.8%/day
Key levels
$21.5052 week high+97.4%
$15.07200 day average+38.4%
$14.99100 day average+37.6%
$14.47Swing high (Oct 12)+32.9%
$13.8650 day average+27.3%
$13.4120 day average+23.1%
$11.26Pivot R1+3.4%
$11.07Pivot+1.7%
$10.89Last close
$10.8752 week low−0.2%
$10.69Pivot S1−1.8%
Indicators
RSI (14)
29.59
Oversold below 30
Oversold
MACD
-0.68
Below its signal line
Bearish
Stochastic
1.8
Near the bottom of its range
Oversold
ADX (14)
21.8
Weak trend
Williams %R
-99.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-147.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.7%
Change over 10 sessions
Bearish
ATR (14)
$0.63
Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 16.1%/day
Key levels
$21.5052 week high+97.4%
$15.07200 day average+38.4%
$14.99100 day average+37.6%
$14.47Swing high (Oct 12)+32.9%
$13.8650 day average+27.3%
$13.4120 day average+23.1%
$11.26Pivot R1+3.4%
$11.07Pivot+1.7%
$10.89Last close
$10.8752 week low−0.2%
$10.69Pivot S1−1.8%
Indicators
RSI (14)
36.88
Weak, oversold below 30
Neutral
MACD
-0.72
Below its signal line
Bearish
Stochastic
19.6
Near the bottom of its range
Oversold
ADX (14)
15.9
No clear trend
Williams %R
-99.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-182.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−29.6%
Change over 10 sessions
Bearish
ATR (14)
$1.75
Typical daily range, 16.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for MESO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MESO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow MESO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MESOHow many large options trades hit MESO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MESO in the last 90 days.
From SEC Form 4 filings by MESO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MESO is in one of them and how their past MESO trades turned out.
Mesoblast is a biotechnology company based in Melbourne, Australia, that develops cell therapies made from mesenchymal cells taken from healthy adult bone marrow. Its lead product, Ryoncil, is approved in the United States to treat a severe complication of bone marrow transplants in children and is sold to physicians at transplant centers. The company is also developing these cells for other inflammatory conditions, including chronic low back pain and heart failure. The cells can be given without donor matching and are produced at industrial scale.